Korro Bio (KRRO) Total Current Liabilities (2018 - 2026)
Korro Bio's (KRRO) quarterly Total Current Liabilities came in at $14.8 million in Q1 2026, up 14.8% YoY from $12.9 million in Q1 2025, and up 23.88% on a QoQ basis from $11.9 million in Q4 2025.
Korro Bio (KRRO) Total Current Liabilities (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Total Current Liabilities data on file, last reported at $14.8 million in Q1 2026.
- Quarterly Total Current Liabilities rose 14.8% year-over-year to $14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 14.8% YoY) and the FY2025 annual result came in at $11.9 million, down 20.21% from the prior year.
- Total Current Liabilities grew to $14.8 million in Q1 2026, from $11.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $22.0 million in Q1 2023 to a low of $8.3 million in Q2 2023.
- A 5-year average of $14.1 million and a median of $13.6 million in 2024 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 123.92% in 2023, down 51.95% in 2023.
- Tracing KRRO's Total Current Liabilities over 5 years: stood at $8.7 million in 2022, then surged by 123.92% to $19.5 million in 2023, then fell by 23.22% to $15.0 million in 2024, then declined by 20.21% to $11.9 million in 2025, then advanced by 23.88% to $14.8 million in 2026.
- The last three Total Current Liabilities figures came in at $14.8 million (Q1 2026), $11.9 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Korro Bio | 235.73 Mn | 120.70 Mn | - | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.63 Mn |
| Mar 31, 2026 | 14.79 Mn |
| Dec 31, 2025 | 11.94 Mn |
| Sep 30, 2025 | 14.64 Mn |
| Jun 30, 2025 | 17.17 Mn |
| Mar 31, 2025 | 12.88 Mn |
| Dec 31, 2024 | 14.96 Mn |
| Sep 30, 2024 | 13.61 Mn |
| Jun 30, 2024 | 12.32 Mn |
| Mar 31, 2024 | 11.05 Mn |
| Dec 31, 2023 | 19.48 Mn |
| Sep 30, 2023 | 9.61 Mn |
| Jun 30, 2023 | 8.33 Mn |
| Mar 31, 2023 | 22.04 Mn |
| Dec 31, 2022 | 8.70 Mn |
| Sep 30, 2022 | 20.00 Mn |
| Jun 30, 2022 | 16.76 Mn |
| Mar 31, 2022 | 12.17 Mn |
| Dec 31, 2021 | 11.43 Mn |
| Sep 30, 2021 | 10.49 Mn |